Monitoring unfractionated heparin therapy: Relationship between eight anti-Xa assays and a protamine titration assay

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 2, 2000, Pages 137-144

  Kitchen, S ^a   Theaker, J ^a   Preston, F E ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Anti Xa; Protamine titration; Unfractionated heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; CHROMOGENIC SUBSTRATE; HEPARIN; PROTAMINE SULFATE; THROMBOPLASTIN; WARFARIN;

ARTICLE; ASSAY; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MONITORING; HEPARINIZATION; HUMAN; INTERNATIONAL STANDARD UNIT; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; TITRIMETRY;

EID: 0033995868     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200011020-00004     Document Type: Article

References (17)

1. 1. Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, et al. A randomised trial comparing APTT with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.
2. 2. Messmore HL, Koza M, Farid S, Wehrmacher WH. Utility of Heptest and a chromogenic substrate method to assess anticoagulation in patients refractory to heparinisation by the Activated Partial Thromboplastin Time method. Semin Thromb Hemost 1994; 20: 351-352.
3. 3. Cirisano FD, Lee S, Greenspoon JS. Apparent heparin resistance from elevated Factor VIII in a patient with postoperative deep venous thrombosis. J Reprod Med 1996; 41: 191-194.
4. 4. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin. Ann Intern Med 1994; 119: 104-109.
5. 5. Kitchen S, Preston FE. The therapeutic range for heparin therapy: relationship between six APTT reagents and two heparin assays. Thromb Haemost 1996; 75: 734-739.
6. 6. Kitchen S, Jennings I, Woods TAL, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring heparin dosage. J Clin Pathol 1996; 49, 10-14.
7. 7. Denson KW, Bonnar J. The measurement of heparin. A method based on the potentiation of anti-factor Xa. Thromb Diath Haemorr 1973; 30: 471-479.
8. 8. Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416.
9. 9. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574.
10. 10. Fischer J, Verbruggen B, Wessels H, Haanen C. The Heptest: possible erroneous results in case of simulstaneous administration of Heparin and Coumarins. Br J Haem 1988; 69: 574-575.
11. 11. Abildgaard U, Nottheim L, Larsen, AE. Monitoring therapy with low molecular weight heparin: a comparison of 3 chromogenic substrate assays and the Heptest clotting assay. Haemostasis 1990; 20: 193-200.
12. 12. Ozawa T, Domagalski J, Mammen EF. Determination of low molecular weight heparin by Heptest on the Automated Coagulation Laboratory system. Am J Clin Pathol 1993; 99: 157-162.
13. 13. Houbouyan LL, Boutiere B, Contant G, Dautzenberg MD, Fievet P, Potron G, et al. Validation protocol of analytical haemostasis systems: measurement of anti Xa activity of low molecular weight heparins. Clin Chem 1996; 42: 1223-1230.
14. 14. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical assessment. Lancet 1986; i: 307-310.
15. 15. Broze GJ, Warren LM, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-343.
16. 16. Sandset PM, Abildgaard U, Larsen ML. Heparin induces the release of extrinsic pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813.
17. 17. Hubbard AR, Weller LJ, Gray E. Measurement of tissue factor inhibitor in normal and post-heparin plasma. Blood Coag Fibrinol 1994; 5: 819-823.